基本情報
研究分野
1経歴
2論文
112-
European heart journal. Cardiovascular Imaging 2023年9月28日
-
In Vivo 37(5) 2320-2326 2023年9月Background/Aim: Accelerated hyperfractionation (AHF) is used in head and neck cancer to improve the local control (LC) rate, but reports of outcomes for early-stage GC are limited. The outcomes of radiotherapy (RT) for stage 1 glottic carcinoma (GC) were retrospectively analyzed, comparing AHF and once-daily fractionation (ODF) using 2.0-2.4 Gy. Patients and Methods: A total of 102 patients with stage 1 GC underwent RT alone between 2007 and 2021, with 43 in the AHF group and 59 in the ODF group. A p-value less than 0.05 was considered to indicate a significant difference. Results: The 5-year LC rate was 98% in the AHF group and 91% in the ODF group (p=0.19). During RT, significantly more patients in the AHF group required opioids due to mucositis than in the ODF group (74% vs. 25%, p<0.001), and the rate of aspiration pneumonia tended to be higher in the AHF group than in the ODF group (7% vs. 0%, p=0.072). Conclusion: There was no difference in the LC rate between AHF and ODF for stage 1 GC. Moreover, the AHF group required opioids at a higher rate and tended to have a higher risk of developing aspiration pneumonia.
-
In Vivo 37(5) 2320-2326 2023年8月31日
-
Cancer reports (Hoboken, N.J.) 6(7) e1825 2023年7月BACKGROUND: Carbon-ion radiotherapy (C-ion RT) is effective for head and neck mucosal melanoma (HN-MM), including radioresistant mucosal melanoma. Melanoma also responds effectively to immune checkpoint inhibitors (ICIs). Data on the efficacy and safety of ICIs for HN-MM are insufficient. AIMS: To analyze the efficacy and safety of ICI salvage therapy in patients with HN-MM recurrence after C-ion RT. METHODS AND RESULTS: This retrospective study analyzed the medical records of 52 patients with HN-MM treated with C-ion RT between 2012 and 2020. A dose of 57.6 or 64.0 Gy (relative biological effectiveness) was provided in 16 fractions. The primary endpoint was 3-year overall survival (OS) rate. The median follow-up time was 26.8 months for all patients. A total of 29 patients had local recurrence or distant metastasis, and 16 patients who received ICI therapy. The 3-year OS rate in the ICI group (n = 16) and best supportive care group (n = 13) were 53.8% and 0.0%, respectively (p = 0.837); the difference was not statistically significant. There were no deaths after 1 year among patients who underwent ICI therapy. No adverse events associated with C-ion RT were related to or exacerbated by ICI. CONCLUSION: ICI salvage therapy is effective and safe for patients with HN-MM recurrence after C-ion RT.
-
Case reports in oncology 16(1) 218-226 2023年QUAD SHOT is an ultra-hypofractionated radiotherapy (RT) technique that prescribes 14.0-14.8 Gy over 2 days. Although this technique has already gained some status as an effective palliative treatment for inoperable head and neck cancer (HNC), its application in other situations has not been given much consideration. Herein, we report a case of a 62-year-old woman who received preoperative QUAD SHOT therapy for poorly differentiated parotid carcinoma. In this case, after two courses of QUAD SHOT plus a standard chemotherapy regimen with pembrolizumab, the patient's inoperable, bulky tumor shrank dramatically and became operable. Best of all, while adequate therapeutic effects were achieved, the patient's time commitment and physical exertion were limited. RT during this period consisted of only eight fractions over 4 days. According to previous reports, the response rate for QUAD SHOT is sufficiently high, and the rate of serious adverse events is quite low. This case asks the question of whether the indications for QUAD SHOT irradiation can be expanded as one of the preoperative interventions undertaken by HNC surgeons to achieve conversion surgery.
MISC
147-
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 72(1) S225-S226 2008年
-
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 72(1) S689-S690 2008年
-
日本放射線影響学会大会講演要旨集 50回 153-153 2007年11月
-
AMERICAN JOURNAL OF GASTROENTEROLOGY 102 S138-S138 2007年9月
-
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 69(3) S239-S240 2007年
-
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 69(3) S608-S609 2007年
-
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 69(3) S599-S600 2007年
-
Neuroscience Research (Supplement) 58(1) S134 2007年 査読有り
-
日本放射線腫瘍学会誌 18(3) 169-169 2006年9月
-
泌尿器外科 19(8) 975-979 2006年8月前立腺癌に対する外照射併用高線量率組織内照射におけるanatomy based inverse optimization(AB-IO)の有効性を評価するため、急性尿路反応および尿道線量を指標にgeometrical optimization(GO)のみで最適化を行った症例と比較検討した。GO群70例、AB-IO群72例を対象とした。RTOG/EORTC toxicity criteriaによる急性反応の最適化方法別のgradingは、GO群:grade 0-1;44例、grade 2-3;26例、AB-IO群:grade 0-1;58例、grade 2-3;14例と、AB-IO群で有意にgrade 2-3の尿路系急性反応が少なく、尿道線量(尿道のV80〜V150)が有意にAB-IO群で低かった。Target coverageおよびconformal indexともにAB-IO群で良好であった。この結果からAB-IOは前立腺への線量を損なうことなく、尿道への線量を低下して急性反応を低減する有効な方法と考えられた。(著者抄録)
-
日本医学放射線学会学術集会抄録集 65回 S163-S163 2006年2月
-
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 66(3) S591-S591 2006年
-
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 66(3) S250-S250 2006年
-
NEUROSCIENCE RESEARCH 55 S120-S120 2006年
-
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 66(3) S387-S388 2006年
共同研究・競争的資金等の研究課題
8-
日本学術振興会 科学研究費助成事業 2020年4月 - 2024年3月
-
日本学術振興会 科学研究費助成事業 2017年4月 - 2022年3月
-
日本学術振興会 科学研究費助成事業 2016年4月 - 2020年3月
-
日本学術振興会 科学研究費助成事業 2014年4月 - 2017年3月
-
日本学術振興会 科学研究費助成事業 2013年4月 - 2016年3月